NLM Digital Collections

Search

Start Over Subjects Cost-Benefit Analysis ✖Remove constraint Subjects: Cost-Benefit Analysis Subjects Rituximab -- therapeutic use ✖Remove constraint Subjects: Rituximab -- therapeutic use

1. Targeted immune modulators for rheumatoid arthritis: effectiveness and value : evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, April 7, 2017
Subject(s):
Arthritis, Rheumatoid -- drug therapy
Arthritis, Rheumatoid -- immunology
Immunologic Factors -- therapeutic use
Abatacept -- therapeutic use
Adalimumab -- therapeutic use
Antirheumatic Agents -- adverse effects
Antirheumatic Agents -- therapeutic use
Certolizumab Pegol -- therapeutic use
Cost-Benefit Analysis
Drug Therapy, Combination
Etanercept -- therapeutic use
Immunologic Factors -- adverse effects
Infliximab -- therapeutic use
Interleukin-6 -- antagonists & inhibitors
Janus Kinase Inhibitors -- therapeutic use
Randomized Controlled Trials as Topic
Rituximab -- therapeutic use
Tumor Necrosis Factors -- antagonists & inhibitors
Humans
United States

2. Targeted immune modulators for rheumatoid arthritis: effectiveness & value : evidence report

Publication:
Boston, MA : Institute for Clinical and Economic Review, March 10, 2017
Subject(s):
Arthritis, Rheumatoid -- drug therapy
Comparative Effectiveness Research
Immunologic Factors -- therapeutic use
Abatacept -- therapeutic use
Adalimumab -- therapeutic use
Certolizumab Pegol -- therapeutic use
Cost-Benefit Analysis
Etanercept -- therapeutic use
Immunologic Factors -- adverse effects
Immunologic Factors -- economics
Immunotherapy
Infliximab -- therapeutic use
Interleukin-6 -- antagonists & inhibitors
Protein Kinase Inhibitors -- therapeutic use
Randomized Controlled Trials as Topic
Rituximab -- therapeutic use
Treatment Outcome
Tumor Necrosis Factor-alpha -- antagonists & inhibitors
Value-Based Purchasing
Humans
United States